Biomarkers of fibrosis, kidney tissue injury and inflammation may predict severity and outcome of renal ANCA - associated vasculitis.
ANCA- associated vasculitis
DKK-3
PRO-C6
biomarkers
chronic kidney disease
kidney biopsy
kidney fibrosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
12
2022
accepted:
24
02
2023
medline:
7
4
2023
entrez:
6
4
2023
pubmed:
7
4
2023
Statut:
epublish
Résumé
Activity and chronicity of kidney involvement in ANCA-associated vasculitis (AAV) can be currently reliably evaluated only by kidney biopsy. In this study, we measured a panel of serum and urinary biomarkers collected at the time of kidney biopsy and hypothesized that they could reflect specific histopathological parameters in the biopsy and help to predict prognosis. We examined a cohort of 45 patients with AAV and 10 healthy controls. Biomarker levels (DKK-3, CD163, EGF, PRO-C6 and C3M) were measured in this study by ELISA. Biopsies were scored with a scoring system for AAV (focal x crescentic x sclerotic x mixed class) and interstitial fibrosis was quantified. Levels of urinary DKK-3, CD163, EGF, PRO-C6 and C3M significantly differed among biopsy classes in AAV, with urinary DKK-3 and PRO-C6 levels being highest in the sclerotic class and lowest in the focal class, urinary CD163 levels highest in the crescentic class and urinary C3M levels highest in the focal class. Moreover, the urinary biomarkers were able to discriminate focal biopsy class from the other classes. Urinary DKK-3, EGF, PRO-C6 and C3M levels measured at the time of biopsy were also significantly related to the extent of fibrosis and to the final kidney function at the end of follow-up. This small pilot study suggests that selected urinary biomarkers of fibrosis and inflammation may reflect changes in the kidney biopsy and be prognostic of kidney outcome in patients with AAV.
Sections du résumé
Background
Activity and chronicity of kidney involvement in ANCA-associated vasculitis (AAV) can be currently reliably evaluated only by kidney biopsy. In this study, we measured a panel of serum and urinary biomarkers collected at the time of kidney biopsy and hypothesized that they could reflect specific histopathological parameters in the biopsy and help to predict prognosis.
Methods
We examined a cohort of 45 patients with AAV and 10 healthy controls. Biomarker levels (DKK-3, CD163, EGF, PRO-C6 and C3M) were measured in this study by ELISA. Biopsies were scored with a scoring system for AAV (focal x crescentic x sclerotic x mixed class) and interstitial fibrosis was quantified.
Results
Levels of urinary DKK-3, CD163, EGF, PRO-C6 and C3M significantly differed among biopsy classes in AAV, with urinary DKK-3 and PRO-C6 levels being highest in the sclerotic class and lowest in the focal class, urinary CD163 levels highest in the crescentic class and urinary C3M levels highest in the focal class. Moreover, the urinary biomarkers were able to discriminate focal biopsy class from the other classes. Urinary DKK-3, EGF, PRO-C6 and C3M levels measured at the time of biopsy were also significantly related to the extent of fibrosis and to the final kidney function at the end of follow-up.
Conclusions
This small pilot study suggests that selected urinary biomarkers of fibrosis and inflammation may reflect changes in the kidney biopsy and be prognostic of kidney outcome in patients with AAV.
Identifiants
pubmed: 37020541
doi: 10.3389/fimmu.2023.1122972
pmc: PMC10067901
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Epidermal Growth Factor
62229-50-9
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1122972Informations de copyright
Copyright © 2023 Satrapova, Sparding, Genovese, Karsdal, Bartonova, Frausova, Honsova, Kollar, Suchanek, Koprivova, Rysava, Bednarova, Tesar and Hruskova.
Déclaration de conflit d'intérêts
NS, FG, and MK are full-time employees at Nordic Bioscience and FG and MK hold stocks. Nordic Bioscience is a privately-owned, small–medium-sized enterprise partly focused on the development of biomarkers and owns the patent for the uC3M and PRO-C6 ELISAs. No authors received fees, bonuses, or other benefits for the work described in the manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Kidney Int. 2003 Feb;63(2):670-7
pubmed: 12631133
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1740-1748
pubmed: 33203735
Kidney Int. 1996 Mar;49(3):656-65
pubmed: 8648906
Clin Kidney J. 2020 Jan 14;14(2):593-601
pubmed: 33623684
Ann Transl Med. 2016 Oct;4(Suppl 1):S62
pubmed: 27868030
Ann Rheum Dis. 2019 Oct;78(10):e111
pubmed: 30061162
Front Physiol. 2020 Dec 16;11:533344
pubmed: 33391006
Nephrol Dial Transplant. 2022 May 25;37(6):1099-1108
pubmed: 33914059
Nat Commun. 2014 Mar 19;5:3485
pubmed: 24647224
Kidney360. 2021 Jun 18;2(9):1473-1481
pubmed: 35373114
Sci Rep. 2019 Nov 5;9(1):16062
pubmed: 31690732
J Am Soc Nephrol. 2016 Sep;27(9):2906-16
pubmed: 26940094
J Am Soc Nephrol. 2010 Oct;21(10):1628-36
pubmed: 20616173
J Pathol. 2019 Jan;247(1):99-109
pubmed: 30246318
Sci Rep. 2022 Mar 8;12(1):4079
pubmed: 35260630
JCI Insight. 2016 Jan 21;1(1):e84916
pubmed: 27699213
Diabetes Care. 2018 Jul;41(7):1493-1500
pubmed: 29643059
J Am Soc Nephrol. 2018 Nov;29(11):2722-2733
pubmed: 30279273
Sci Rep. 2017 Dec 11;7(1):17328
pubmed: 29229941
Front Immunol. 2020 Apr 15;11:671
pubmed: 32351512
PLoS One. 2017 Apr 12;12(4):e0175200
pubmed: 28403201
Ann Rheum Dis. 2018 Sep;77(9):1339-1344
pubmed: 29724728
Am J Transplant. 2017 Jan;17(1):28-41
pubmed: 27862883
Nephrol Dial Transplant. 2004 Jun;19(6):1403-11
pubmed: 15069175
Nephrol Dial Transplant. 2017 Feb 1;32(2):248-253
pubmed: 28186571